DOI: 10.36347/sjmcr.2015.v03i11.003

Pages: 1019-1021

Cigarette smoking is one of the most common causes of preventable mortality. Bupropion is a new-generation monocyclic antidepressant used orally in the treatment of depression, seasonal affective disorder and smoking cessation. It is known to function by inhibiting dopamine and norepinephrin uptake. Its potential effect in reducing nicotine dependence was discovered by chance. Bupropion is the first non-nicotine agent approved by the FDA in smoking cessation. The clinical effects following overdosing occur primarily in the neurological, cardiovascular and gastrointestinal systems. In addition to these systems, it can cause potentially life-threatening psychiatric side-effects such as suicidal ideation, agitation, psychosis and mania. The purpose of this report is to describe the psychiatric side-effects in therapeutic doses and excessive doses of bupropion.